Skip to main content
. 2020 Dec 14;11:579525. doi: 10.3389/fphar.2020.579525

FIGURE 4.

FIGURE 4

(A), The HR value of CEs in comparing the two different LQT genotypes, including LQT2 vs. LQT1, LQT3 vs. LQT1, and LQT3 vs. LQT2. (B), the effectiveness of BBs in reducing the occur of CEs via comparsing LQT2 and LQT1 (LQT2 vs. LQT1). (C), The efficacy of different BBs on the risk reduction of CEs in LQT1 and LQT2. (D), The efficacy of BBs therapy on managing of CEs in different LQTs genotypes, including LQT1, LQT2, LQT3. (E), The efficacy of BBs therapy in reducing the incidence of syncope or ACA respectively.